Brain Cancer Clinical Trials in North Carolina

Showing 61-80 of 212 trials

Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma

NCT03868943

This phase II trial studies the side effects of solriamfetol in improving sleep in patients with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug. Giving solriamfetol may improve sleep, memory, fatigue, mood, or quality of life in patients with brain tumors (gliomas).

GliomaGlioblastoma

Wake Forest University Health Sciences2 participantsStarted Jan 2021

Winston-Salem, North Carolina, United States

COMPLETED41 miles

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

NCT02392078

The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical. Since it received FDA clearance in May 2009, the NBS has been used in over 2600 procedures conducted at over 70 leading institutions across United States. This is a prospective, multi-center registry that will include data collection up to 5 years to evaluate safety, QoL, and procedural outcomes including local control failure rate, progression free survival, overall survival, and seizure freedom in up to 3,000 patients and up to 50 sites.

Metastatic Brain TumorPrimary Brain TumorEpileptic/Seizure Foci+1 more

Monteris Medical1,153 participantsStarted Oct 2015

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • La Jolla, California, United States +23 more locations

Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

Brain Cancer Trials in Other Cities

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

A Study of Abemaciclib in Recurrent Glioblastoma

A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma

Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma

VB-111 in Surgically Accessible Recurrent/Progressive GBM

Other Conditions in North Carolina